Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02267733 · ClinicalTrials.gov registry record · Phase 1
Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing In Gammopathy Patients
A Phase 1 study of Influenza and Gammopathy, sponsored by Yale University.
- Completed
- Registry status
- Phase 1
- Development phase
- 51
- Enrollment target
- 1
- Study location
NCT02267733 is a Phase 1 study of Influenza and Gammopathy that has completed, run by Yale University. The registered enrollment target is 51 participants, below the 36,804-participant average among 156 other Influenza trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02267733, a Phase 1 study of Influenza and Gammopathy, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 51 participants
- Enrollment target
- 1
- Study location
Study Summary
A Pilot Study utilizing high dose trivalent influenza vaccine dose in a booster dosing schedule for patients with monoclonal gammopathies stratified by disease status
Conditions Studied
Interventions
- DRUG Fluzone
Study Locations (1)
Connecticut
- Yale University - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2014-10 |
| Est. Completion | 2015-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02267733
The ClinicalTrials.gov registry entry for NCT02267733 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 36,804-participant average among 156 other Influenza trials with a reported enrollment target (100% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Influenza appearing as the primary indexed condition, and to 1 intervention - of which Fluzone is the first listed.
NCT02267733 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT02267733 about?
NCT02267733 is a clinical study titled "Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing In Gammopathy Patients". A Pilot Study utilizing high dose trivalent influenza vaccine dose in a booster dosing schedule for patients with monoclonal gammopathies stratified by disease status
What is the current status of trial NCT02267733?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 51 participants. The study started on 2014-10. Estimated completion is 2015-12.
What conditions does trial NCT02267733 study?
This clinical trial studies the following conditions: Influenza, Gammopathy.
What interventions are being tested in trial NCT02267733?
The interventions under investigation include: Fluzone (DRUG).
Who is sponsoring clinical trial NCT02267733?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02267733 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Influenza
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
pH1N1 Blinded Challenge Study
RECRUITING · Phase 1
-
A/Texas Flu Challenge
RECRUITING · Phase 1
-
First-in-Human Study of VNT-101: Safety, Tolerability, and Pharmacokinetics
RECRUITING · Phase 1
-
Influenza Human Challenge Model
RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults
ACTIVE NOT RECRUITING · Phase 1
-
Pilot Influenza Challenge Study
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.